Philip Morris International Inc. (PM) SEC Filings & Earnings Calls
EquiReason read 32 Philip Morris International Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-10-23 — PMI reported Q3 2026 results with net revenue +5.5%, operating income +14.1%, and diluted EPS of $2.12, down 4.9% YoY due to non-cash charges..
Source: SEC EDGAR filings · figures as of 2026-09-30 · read by EquiReason
- Market cap
- 310.9B
- P/E TTM
- 29.1
- Dividend yield
- 3.0%
- 52-week
- —
- Next earnings
- 4 Feb, in 103 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
23 Oct 202610-QPMI reported Q3 2026 results with net revenue +5.5%, operating income +14.1%, and diluted EPS of $2.12, down 4.9% YoY due to non-cash charges.earningsopen
Figures in the filing · each found in the filing text
| Net revenues · 9M-2026 | $32.78B | +8% y/y |
| Net earnings attributable to PMI · 9M-2026 | $8.57B | -7% y/y |
| Diluted earnings per share · 9M-2026 | $5.48 | -7% y/y |
| Net cash provided by operating activities · 9M-2026 | $10.45B | +39% y/y |
| Smoke-free product shipment volume · 9M-2026 | 143,400,000,000 | +6% y/y |
| HTU shipment volume · 9M-2026 | 124,500,000,000 | +7% y/y |
| ZYN U.S. shipment volume (Q3) · U.S. · Q3-2026 | 3,200,000,000 | +4% y/y |
| Effective tax rate · 9M-2026 | 20.9% | |
| Capital expenditures · 9M-2026 | $1.11B | -1% y/y |
| Dividends paid · 9M-2026 | $6.90B | +9% y/y |
Guidance
FY2026: total PMI shipment volume expected to grow (previously broadly stable to slightly growing); high single-digit SFP shipment growth; operating cash flow ~$13.5B; capex $1.4B-$1.6B; effective tax rate ~21.5%
PMI raised its full-year shipment volume outlook to growing (from broadly stable to slightly growing), expects high single-digit SFP growth, but guided to an abnormally low U.S. profitability in Q4 due to investments.
Risks flagged
U.S. Profitability Investment Impact
“We expect an abnormally low level of U.S. profitability in the fourth quarter.” · word for word
RBH Equity Investment Impairment
“PMI recorded a non-cash impairment charge of $511 million in the second quarter of 2026.”
Russia/Ukraine Geopolitical Risk
“For the nine months ended September 30, 2026, our Russian operations accounted for around 7% of our total net revenues.” · word for word
Energy Cost Inflation
“Gross profit, excluding currency and acquisitions/divestitures, increased by 9.8% due to the same factors as for net revenues, slightly offset by higher costs due to increases in energy-related input prices.” · word for word
ZYN Litigation
“Claims have been filed against PMI and one or more subsidiaries related to ZYN nicotine pouches.” · word for word
21 Oct 20268-K · 2.02PMI reports Q3 2026: revenue $11.4B (+5.5%), adj. EPS $2.36 (+5.4%), organic op income +10.5%, margin expansion, record highs. Raises FY2026 adj. EPS forecast to $8.29-$8.44 from $7.54 (+9.9-11.9%), revenue growth 5-7% organic, capex $1.4-1earningsopen
Figures in the filing · each found in the filing text
| Net revenues · PMI · Q3-2026 | $11.44B | +6% y/y |
| Adjusted diluted EPS · Q3-2026 | $2.36 | +5% y/y |
| Reported diluted EPS · Q3-2026 | $2.12 | -5% y/y |
| HTU shipment volume · International Smoke-Free · Q3-2026 | 41,500,000,000 | +2% y/y |
| ZYN shipment volume · U.S. · Q3-2026 | 3,200,000,000 | +4% y/y |
| VEEV shipment growth · E-vapor SFP · Q3-2026 | 61.6% | |
| Operating cash flow · FY2026 | $13.50B |
Guidance
FY26 adjusted diluted EPS raised to $8.29-$8.44 from $7.54; net revenue growth 5-7% organic; organic op income growth 7-9%; capex $1.4-1.6B; operating cash flow ~$13.5B
FY2026 guidance raised: adj. EPS $8.29-$8.44, revenue growth 5-7% organic, op income growth 7-9% organic, capex $1.4-1.6B.
Risks flagged
Geopolitical tensions and U.S. growth investments may pressure margins.
“Cost impacts of ongoing geopolitical tensions and the previously communicated step-up in U.S. growth investments.” · word for word
No share repurchases planned, limiting capital return.
“No share repurchases.”
18 Sep 20268-K · 7.01PMI increased regular quarterly dividend by 8.8% to $1.60/share ($6.40 annualized), up from $1.47/share. Consistent with long-term dividend growth trend.open
Figures in the filing · each found in the filing text
| dividend per share (quarterly) · Q4-2026 | $1.60 | +9% y/y |
8 Sep 20268-K · 7.01PMI raises 2026 full-year adjusted diluted EPS forecast to $8.35-$8.50, representing 10.7%-12.7% growth vs 2025, driven by currency tailwinds and operational momentum.open
Guidance
Adjusted diluted EPS raised to $8.35-$8.50 from prior range; growth of 10.7%-12.7% YoY
PMI raises full-year adjusted diluted EPS guidance, citing currency tailwinds and operational momentum, with strong smoke-free product performance.
Risks flagged
Currency tailwind may reverse; regulatory and litigation risks persist.
“Currency impact of $0.24 per share; risk factors include excise taxes, litigation, and regulatory restrictions.”
8 Sep 20268-K · 7.01PMI raised 2026 adj. diluted EPS forecast to $8.35-$8.50 (10.7%-12.7% growth), including favorable currency of $0.24; Q3 EPS forecast $2.29-$2.34.open
Figures in the filing · each found in the filing text
| Adjusted Diluted EPS · FY2026 | $8.35 | +11% y/y |
| Adjusted Diluted EPS (ex-currency) · FY2026 | $8.11 | +8% y/y |
| Q3 Adjusted Diluted EPS · Q3-2026 | $2.29 |
Guidance
FY2026 adj. diluted EPS raised to $8.35-$8.50 from prior; 10.7%-12.7% growth
PMI raised FY2026 EPS guidance on strong smoke-free product demand and currency tailwind.
Risks flagged
Currency volatility could impact reported EPS; guidance includes $0.24 favorable currency.
“incl. favorable currency impact of 24 cents” · word for word
24 Aug 20268-K · 7.01PMI enters contract manufacturing arrangement with Altria for combustible cigarettes; first shipments expected early 2027; no material 2026 impact; no US commercialization.open
Risks flagged
Operational readiness and regulatory requirements may delay first shipments beyond early 2027.
“subject to operational readiness and applicable regulatory requirements” · word for word
24 Jul 202610-QPMI reported Q2 2026 results with improved operating cash flow and maintained capex guidance, but faces ongoing risks from Russia exposure and smoke-free product commercialization.earningsopen
Figures in the filing · each found in the filing text
| Net cash provided by operating activities · H1-2026 | $5.09B | +66% y/y |
| Cash and cash equivalents · Q2-2026 | $6.00B | |
| Total debt · Q2-2026 | $49.10B | |
| Dividend per share (annualized) · Q3-2025 | $5.88 | +9% y/y |
Guidance
FY2026 net cash provided by operating activities around $13.5B; capex $1.4B-$1.6B
PMI reaffirmed full-year 2026 guidance for operating cash flow (~$13.5B) and capex ($1.4B-$1.6B), with no change in demand or margin outlook.
Risks flagged
Russia asset impairment risk
“In the event of a divestment, our ability to fully realize the value of the business would likely be subject to material impairment.” · word for word
Smoke-free product regulatory risk
“Our strategic priority is the continued introduction, commercialization, and growth of our SFPs, and if these efforts are not successful, in key markets or systematically, our financial results and future growth prospects may be materially adversely impacted.” · word for word
Currency devaluation risk
“Capital controls and/or foreign currency exchange constraints may affect the ability of our subsidiaries in impacted jurisdictions to settle foreign currency denominated imports of goods and services and/or to pay dividends and royalties.” · word for word
22 Jul 20268-K · 2.02Net Revenues $11.20B (+10% y/y); Reported Diluted EPS $1.80 (-8% y/y); Adjusted Diluted EPS $2.20 (+15% y/y); Guidance: Updated full-year adjusted diluted EPS forecast for currency onlyearningsopen
Figures in the filing · each found in the filing text
| Net Revenues · Q2-2026 | $11.20B | +10% y/y |
| Reported Diluted EPS · Q2-2026 | $1.80 | -8% y/y |
| Adjusted Diluted EPS · Q2-2026 | $2.20 | +15% y/y |
| Smoke-Free Shipment Volume Growth · Smoke-Free · Q2-2026 | 7.5% | |
| IQOS HTU Adjusted IMS Growth (ex Japan & Poland) · Smoke-Free · Q2-2026 | 10.0% | |
| ZYN Shipments · U.S. · Q2-2026 | 2,900,000,000 | +2% y/y |
| VEEV Shipment Growth · E-vapor · Q2-2026 | 55.1% |
Guidance
Updated full-year adjusted diluted EPS forecast for currency only
Well positioned to deliver on full-year targets while investing for future growth.
Risks flagged
Transient headwinds in Japan and Poland due to excise-driven price increase and flavor ban.
“Expected transient headwinds in Japan and Poland; HTU adjusted IMS in Japan declined by estimated 3.4%.” · word for word
2 Jun 20268-K · 7.01Non-cash impairment of RBH equity investment $500M; Guidance: Adjusted diluted EPS forecast raised to $8.31-$8.46 from prior; growth 10.2%-12.2% vs 2025open
Figures in the filing · each found in the filing text
| Non-cash impairment of RBH equity investment · RBH · Q2-2026 | $500M |
Guidance
Adjusted diluted EPS forecast raised to $8.31-$8.46 from prior; growth 10.2%-12.2% vs 2025
PMI raised its FY2026 adjusted diluted EPS forecast, reflecting strong smoke-free business momentum and despite a non-cash impairment charge.
Risks flagged
Non-cash impairment of RBH investment due to updated projections reflecting current industry dynamics.
“PMI's Canadian affiliate, RBH, provided an updated five-year financial projections reflecting current industry dynamics. As a result, PMI expects to record a non-cash impairment charge of approximately $500 million.” · word for word
20 May 20268-K · 5.02, 7.01PMI appoints Massimo Andolina as Group CFO effective Aug 1, 2026, replacing Emmanuel Babeau who stays as advisor through Mar 2027. Succession is orderly, no compensation disclosed yet.open
Risks flagged
No immediate financial risk; transition risk is low due to internal promotion and advisory period.
“Orderly succession with internal candidate and outgoing CFO staying as advisor.”
24 Apr 202610-QOperating Cash Flow $-399M (-14% y/y); Capital Expenditures $353M (-13% y/y); Total Debt $51.90B; Guidance: FY 2026 operating cash flow ~$13.5B; capex $1.4B-$1.6Bopen
Figures in the filing · each found in the filing text
| Operating Cash Flow · Q1-2026 | $-399M | -14% y/y |
| Capital Expenditures · Q1-2026 | $353M | -13% y/y |
| Total Debt · 2026-03-31 | $51.90B | |
| Cash and Cash Equivalents · 2026-03-31 | $5.50B | |
| Commercial Paper Outstanding · 2026-03-31 | $5.50B |
Guidance
FY 2026 operating cash flow ~$13.5B; capex $1.4B-$1.6B
FY 2026 operating cash flow expected ~$13.5B; capex $1.4B-$1.6B primarily for smoke-free capacity; tariff impact not material in Q1.
Risks flagged
Russia Asset Impairment Risk
“As of March 31, 2026, our Russian operations had approximately $5.0 billion in total assets... In the event of a divestment, our ability to fully realize the value of the business would likely be subject to material impairment.” · word for word
Excise Tax Pressure
“Excessive and disruptive excise, sales and other tax increases and discriminatory tax structures are expected to continue to have an adverse impact on our profitability.” · word for word
Tariff Volatility
“We expect the global tariff environment to remain volatile throughout 2026.” · word for word
Regulatory Restrictions on SFPs
“Some governments have, or are seeking to, ban or severely restrict emerging tobacco and nicotine-containing products, such as our SFPs.” · word for word
22 Apr 20268-K · 2.02Net revenues $10.10B (+9% y/y); Adjusted Diluted EPS $1.96 (+16% y/y); Reported Diluted EPS $1.56 (-9% y/y); Guidance: Updated full-year adjusted diluted EPS forecast for currency only; no change to underlying guidance.earningsopen
Figures in the filing · each found in the filing text
| Net revenues · Q1-2026 | $10.10B | +9% y/y |
| Adjusted Diluted EPS · Q1-2026 | $1.96 | +16% y/y |
| Reported Diluted EPS · Q1-2026 | $1.56 | -9% y/y |
| HTU adjusted IMS volume growth · International Smoke-Free · Q1-2026 | 10.9% | |
| ZYN shipments · U.S. · Q1-2026 | 2,300,000,000 | -24% y/y |
| ZYN offtake volume growth (Nielsen) · U.S. · Q1-2026 | 10.0% |
Guidance
Updated full-year adjusted diluted EPS forecast for currency only; no change to underlying guidance.
Management expressed strong momentum and best-in-class performance outlook, but only adjusted EPS forecast for currency.
Risks flagged
U.S. regulatory uncertainty for nicotine pouch innovations like ZYN ULTRA under FDA review.
“ZYN ULTRA, which remains under active FDA review as part of the nicotine pouch pilot program.” · word for word
Flavor ban in Poland impacted IQOS volumes; potential for broader regulatory headwinds in Europe.
“initial impact of the characterizing flavor ban in Poland, which was implemented in January.” · word for word
26 Mar 2026DEF 14AProxy statement filed for annual shareholder meeting; no material event.open
Figures in the filing · each found in the filing text
| Smoke-Free Net Revenues · Smoke-Free · FY2025 | $16.85B | +15% y/y |
| Adjusted Operating Income · FY2025 | $16.43B | +12% y/y |
| Operating Cash Flow · FY2025 | $12.20B | |
| Smoke-Free Shipment Volume · Smoke-Free · FY2025 | 176,900,000,000 | |
| Adjusted Diluted EPS · FY2025 | $7.54 | +15% y/y |
| Net Income · FY2025 | $11.85B |
Risks flagged
Regulatory and excise tax risk for smoke-free products
“regulatory and excise tax differentiation between SFPs and cigarettes that appropriately reflects the product risk continuum remains a priority” · word for word
Geopolitical and macroeconomic volatility
“The global economic environment remains challenging and volatile.” · word for word
5 Mar 20268-K · 7.01Quarterly dividend per share $1.47open
Figures in the filing · each found in the filing text
| quarterly dividend per share · Q2-2026 | $1.47 |
18 Feb 20268-K · 7.01Smoke-free net revenues $17.00B; Smoke-free net revenues as % of total 41.5open
Figures in the filing · each found in the filing text
| Smoke-free net revenues · Smoke-Free · FY2025 | $17.00B | |
| Smoke-free net revenues as % of total · Smoke-Free · FY2025 | 41.5% |
18 Feb 20268-K · 7.01Reported diluted EPS $7.87; Adjusted diluted EPS $8.38 (+11% y/y); Guidance: Adjusted diluted EPS $8.38-$8.53, growth 11.1%-13.1% YoYopen
Figures in the filing · each found in the filing text
| Reported diluted EPS · FY2026 | $7.87 | |
| Adjusted diluted EPS · FY2026 | $8.38 | +11% y/y |
Guidance
Adjusted diluted EPS $8.38-$8.53, growth 11.1%-13.1% YoY
Reaffirmed 2026 adjusted diluted EPS forecast with strong growth; smoke-free transformation driving momentum.
Risks flagged
Currency headwinds; favorable currency impact of $0.27 per share included in forecast.
“Excluding favorable currency impact of $0.27 per share, growth 7.5%-9.5%.”
6 Feb 20268-K · 2.02Net revenues $40.60B (+7% y/y); Adjusted diluted EPS $7.54 (+15% y/y); Smoke-free business net revenues $16.90B (+15% y/y); Guidance: 2026-2028 growth targets renewed; 2024-2026 CAGR targets achieved in 2 yearsearningsopen
Figures in the filing · each found in the filing text
| Net revenues · FY2025 | $40.60B | +7% y/y |
| Adjusted diluted EPS · FY2025 | $7.54 | +15% y/y |
| Smoke-free business net revenues · Smoke-free business · FY2025 | $16.90B | +15% y/y |
| ZYN shipment volume · Oral SFP · FY2025 | 794,000,000 | |
| HTU adjusted IMS growth · Heat-not-burn SFP · FY2025 | 10.5% | |
| Reported diluted EPS · FY2025 | $7.26 | +61% y/y |
| Gross profit · FY2025 | $27.30B | +11% y/y |
| Operating income · FY2025 | $14.90B | |
| Dividend per share (annualized) · FY2026 | $5.88 |
Guidance
2026-2028 growth targets renewed; 2024-2026 CAGR targets achieved in 2 years
PMI raised its medium-term growth targets for 2026-2028, citing strong smoke-free momentum and margin expansion.
Risks flagged
Regulatory and competitive risks in smoke-free category; intensifying competition in Japan and other markets.
“notwithstanding intensifying competition” · word for word
6 Feb 202610-KRussia shipment volume share 9; Russia net revenue share 6; Ukraine shipment volume share 2open
Figures in the filing · each found in the filing text
| Russia shipment volume share · FY2025 | 9.0% | |
| Russia net revenue share · FY2025 | 6.0% | |
| Ukraine shipment volume share · FY2025 | 2.0% | |
| Ukraine net revenue share · FY2025 | 1.0% |
Risks flagged
Russia/Ukraine conflict
“The full implications of the Russian invasion of Ukraine for our operations in those countries are impossible to predict at this time.” · word for word
Regulatory tax pressure
“In July 2025, the EU Commission published a legislative proposal for the revision of the 2011 EU Tobacco Excise Directive.” · word for word
Flavor bans
“All EU Member States were required to apply the delegated directive as of October 23, 2023, which bans the use of characterizing flavors in heated tobacco products.” · word for word
15 Jan 20268-K · 7.01U.S.-related investments $20.00B; charitable giving $12Mopen
Figures in the filing · each found in the filing text
| U.S.-related investments · since 2022 | $20.00B | |
| charitable giving · 2025 | $12M |
Risks flagged
Future investments contingent on FDA authorization for IQOS ILUMA; regulatory risk remains.
“PMI U.S. stands ready to support continued growth and further increase its investments following the launch of the IQOS ILUMA product, which is pending FDA authorization.” · word for word
12 Dec 20258-K · 7.01Dividend per share $1.47open
Figures in the filing · each found in the filing text
| dividend per share · Q4-2025 | $1.47 |
Risks flagged
No material risk disclosed.
2 Dec 20258-K · 7.01Guidance: Adjusted diluted EPS $7.46-$7.56open
Guidance
Adjusted diluted EPS $7.46-$7.56
Reaffirmed FY2025 EPS guidance with 13.5%-15.1% growth; assumptions unchanged.
Risks flagged
Currency headwinds and regulatory/tax risks remain, but guidance assumes stable conditions.
“Currency impact of $0.10 per share; risks include excise taxes, regulatory restrictions, litigation.”
17 Nov 20258-K · 8.01Aggregate principal amount of notes outstanding $1.70Bopen
Figures in the filing · each found in the filing text
| aggregate principal amount of notes outstanding · 2025-11-17 | $1.70B |
4 Nov 20258-K · 5.02, 7.01Smoke-free business % of total net revenues 41; smoke-free product markets 100; smoke-free product users 41,000,000open
Figures in the filing · each found in the filing text
| smoke-free business % of total net revenues · 9M-2025 | 41.0% | |
| smoke-free product markets · 2025-06-30 | 100 | |
| smoke-free product users · 2025-06-30 | 41,000,000 | |
| cumulative investment in smoke-free · 2008-2025 | $14.00B |
24 Oct 202510-QPMI reported strong Q3 2025 results with revenue +9.4% and EPS +13.2% YoY, driven by smoke-free volume and pricing.earningsopen
Figures in the filing · each found in the filing text
| Net Revenues · Q3-2025 | $10.80B | +9% y/y |
| Diluted EPS · Q3-2025 | $2.23 | +13% y/y |
| Net Cash Provided by Operating Activities · 9M-2025 | $7.52B | -8% y/y |
| Capital Expenditures · 9M-2025 | $1.13B | -4% y/y |
| Dividend per Share (Quarterly) · Q3-2025 | $1.47 | +9% y/y |
Guidance
Full-year operating cash flow expected >$11.5B; capex ~$1.6B
PMI reaffirmed strong cash flow guidance and continues to invest in smoke-free capacity.
Risks flagged
Russia/Ukraine Exposure
“As of September 30, 2025, our Russian operations had approximately $4.5 billion in total assets, excluding intercompany balances, of which approximately $2.0 billion consisted of cash and cash equivalents held mostly in local currency (Russian rubles).” · word for word
Regulatory Litigation
“Germany excise tax classification litigation charge... $176 million... recorded as a pre-tax charge.”
Wellness & Healthcare Impairment
“Impairment of Wellness & Healthcare related equity investment... $146 million.” · word for word
Philip Morris International Inc. — questions
- What did Philip Morris International Inc. file recently?
- 32 SEC filings in the last 12 months. Latest: 10-Q on 2026-10-23 — PMI reported Q3 2026 results with net revenue +5.5%, operating income +14.1%, and diluted EPS of $2.12, down 4.9% YoY due to non-cash charges.
Every figure on this page comes from Philip Morris International Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.